Literature DB >> 19755855

Amplification of chromosomal segment 4q12 in non-small cell lung cancer.

Alex H Ramos1, Amit Dutt, Craig Mermel, Sven Perner, Jeonghee Cho, Christopher J Lafargue, Laura A Johnson, Ann-Cathrin Stiedl, Kumiko E Tanaka, Adam J Bass, Jordi Barretina, Barbara A Weir, Rameen Beroukhim, Roman K Thomas, John D Minna, Lucian R Chirieac, Neal I Lindeman, Thomas Giordano, David G Beer, Patrick Wagner, Ignacio I Wistuba, Mark A Rubin, Matthew Meyerson.   

Abstract

In cancer, proto-oncogenes are often altered by genomic amplification. Here we report recurrent focal amplifications of chromosomal segment 4q12 overlapping the proto-oncogenes PDGFRA and KIT in non-small cell lung cancer (NSCLC). Single nucleotide polymorphism (SNP) array and fluorescent in situ hybridization (FISH) analysis indicate that 4q12 is amplified in 3-7% of lung adenocarcinomas and 8-10% of lung squamous cell carcinomas. In addition, we demonstrate that the NSCLC cell line NCI-H1703 exhibits focal amplification of PDGFRA and is dependent on PDGFRalpha activity for cell growth. Treatment of NCI-H1703 cells with PDGFRA-specific shRNAs or with the PDGFRalpha/KIT small molecule inhibitors imatinib or sunitinib leads to cell growth inhibition. However, these observations do not extend to NSCLC cell lines with lower-amplitude and broader gains of chromosome 4q. Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFRalpha/KIT inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19755855      PMCID: PMC2833355          DOI: 10.4161/cbt.8.21.9764

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  44 in total

1.  A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.

Authors:  Jason Moffat; Dorre A Grueneberg; Xiaoping Yang; So Young Kim; Angela M Kloepfer; Gregory Hinkle; Bruno Piqani; Thomas M Eisenhaure; Biao Luo; Jennifer K Grenier; Anne E Carpenter; Shi Yin Foo; Sheila A Stewart; Brent R Stockwell; Nir Hacohen; William C Hahn; Eric S Lander; David M Sabatini; David E Root
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

2.  Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.

Authors:  Hongbin Ji; Xiaojun Zhao; Yuki Yuza; Takeshi Shimamura; Danan Li; Alexei Protopopov; Boonim L Jung; Kate McNamara; Huili Xia; Karen A Glatt; Roman K Thomas; Hidefumi Sasaki; James W Horner; Michael Eck; Albert Mitchell; Yangping Sun; Ruqayyah Al-Hashem; Roderick T Bronson; Sridhar K Rabindran; Carolyn M Discafani; Elizabeth Maher; Geoffrey I Shapiro; Matthew Meyerson; Kwok-Kin Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-03       Impact factor: 11.205

3.  Common and contrasting genomic profiles among the major human lung cancer subtypes.

Authors:  G Tonon; C Brennan; A Protopopov; G Maulik; B Feng; Y Zhang; D B Khatry; M J You; A J Aguirre; E S Martin; Z Yang; H Ji; L Chin; K-K Wong; R A Depinho
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2005

4.  TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.

Authors:  S Perner; P L Wagner; A Soltermann; C LaFargue; V Tischler; B A Weir; W Weder; M Meyerson; T J Giordano; H Moch; M A Rubin
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996

5.  Somatic mutations affect key pathways in lung adenocarcinoma.

Authors:  Li Ding; Gad Getz; David A Wheeler; Elaine R Mardis; Michael D McLellan; Kristian Cibulskis; Carrie Sougnez; Heidi Greulich; Donna M Muzny; Margaret B Morgan; Lucinda Fulton; Robert S Fulton; Qunyuan Zhang; Michael C Wendl; Michael S Lawrence; David E Larson; Ken Chen; David J Dooling; Aniko Sabo; Alicia C Hawes; Hua Shen; Shalini N Jhangiani; Lora R Lewis; Otis Hall; Yiming Zhu; Tittu Mathew; Yanru Ren; Jiqiang Yao; Steven E Scherer; Kerstin Clerc; Ginger A Metcalf; Brian Ng; Aleksandar Milosavljevic; Manuel L Gonzalez-Garay; John R Osborne; Rick Meyer; Xiaoqi Shi; Yuzhu Tang; Daniel C Koboldt; Ling Lin; Rachel Abbott; Tracie L Miner; Craig Pohl; Ginger Fewell; Carrie Haipek; Heather Schmidt; Brian H Dunford-Shore; Aldi Kraja; Seth D Crosby; Christopher S Sawyer; Tammi Vickery; Sacha Sander; Jody Robinson; Wendy Winckler; Jennifer Baldwin; Lucian R Chirieac; Amit Dutt; Tim Fennell; Megan Hanna; Bruce E Johnson; Robert C Onofrio; Roman K Thomas; Giovanni Tonon; Barbara A Weir; Xiaojun Zhao; Liuda Ziaugra; Michael C Zody; Thomas Giordano; Mark B Orringer; Jack A Roth; Margaret R Spitz; Ignacio I Wistuba; Bradley Ozenberger; Peter J Good; Andrew C Chang; David G Beer; Mark A Watson; Marc Ladanyi; Stephen Broderick; Akihiko Yoshizawa; William D Travis; William Pao; Michael A Province; George M Weinstock; Harold E Varmus; Stacey B Gabriel; Eric S Lander; Richard A Gibbs; Matthew Meyerson; Richard K Wilson
Journal:  Nature       Date:  2008-10-23       Impact factor: 49.962

6.  Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

Authors:  Eva Wardelmann; Sabine Merkelbach-Bruse; Katharina Pauls; Nadja Thomas; Hans-Ulrich Schildhaus; Thomas Heinicke; Nicola Speidel; Torsten Pietsch; Reinhard Buettner; Daniel Pink; Peter Reichardt; Peter Hohenberger
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

7.  DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers.

Authors:  W W Lockwood; R Chari; B P Coe; L Girard; C Macaulay; S Lam; A F Gazdar; J D Minna; W L Lam
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

8.  PIK3CA mutations and copy number gains in human lung cancers.

Authors:  Hiromasa Yamamoto; Hisayuki Shigematsu; Masaharu Nomura; William W Lockwood; Mitsuo Sato; Naoki Okumura; Junichi Soh; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Hiroshi Date; Wan L Lam; John D Minna; Adi F Gazdar
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

9.  Drug-sensitive FGFR2 mutations in endometrial carcinoma.

Authors:  Amit Dutt; Helga B Salvesen; Tzu-Hsiu Chen; Alex H Ramos; Robert C Onofrio; Charlie Hatton; Richard Nicoletti; Wendy Winckler; Rupinder Grewal; Megan Hanna; Nicolas Wyhs; Liuda Ziaugra; Daniel J Richter; Jone Trovik; Ingeborg B Engelsen; Ingunn M Stefansson; Tim Fennell; Kristian Cibulskis; Michael C Zody; Lars A Akslen; Stacey Gabriel; Kwok-Kin Wong; William R Sellers; Matthew Meyerson; Heidi Greulich
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-13       Impact factor: 11.205

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

View more
  41 in total

Review 1.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

Review 2.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

3.  RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.

Authors:  Bruno Bockorny; Maria Rusan; Wankun Chen; Rachel G Liao; Yvonne Li; Federica Piccioni; Jun Wang; Li Tan; Aaron R Thorner; Tianxia Li; Yanxi Zhang; Changhong Miao; Therese Ovesen; Geoffrey I Shapiro; David J Kwiatkowski; Nathanael S Gray; Matthew Meyerson; Peter S Hammerman; Adam J Bass
Journal:  Mol Cancer Ther       Date:  2018-04-13       Impact factor: 6.261

4.  Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.

Authors:  Marcin Imielinski; Heidi Greulich; Bethany Kaplan; Luiz Araujo; Joseph Amann; Leora Horn; Joan Schiller; Miguel A Villalona-Calero; Matthew Meyerson; David P Carbone
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

5.  Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer.

Authors:  Xiaozheng Zhao; Kenneth E Huffman; Junya Fujimoto; Jamie Rodriguez Canales; Luc Girard; Guangjun Nie; John V Heymach; Igacio I Wistuba; John D Minna; Yonghao Yu
Journal:  J Am Soc Mass Spectrom       Date:  2017-07-27       Impact factor: 3.109

6.  Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.

Authors:  Youngwook Kim; Peter S Hammerman; Jaegil Kim; Ji-ae Yoon; Yoomi Lee; Jong-Mu Sun; Matthew D Wilkerson; Chandra Sekhar Pedamallu; Kristian Cibulskis; Yeong Kyung Yoo; Michael S Lawrence; Petar Stojanov; Scott L Carter; Aaron McKenna; Chip Stewart; Andrey Y Sivachenko; In-Jae Oh; Hong Kwan Kim; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Kyu-Sik Kim; Sang-Yun Song; Kook-Joo Na; Yoon-La Choi; D Neil Hayes; Jhingook Kim; Sukki Cho; Young-Chul Kim; Jin Seok Ahn; Myung-Ju Ahn; Gad Getz; Matthew Meyerson; Keunchil Park
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

7.  FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Authors:  Murry W Wynes; Trista K Hinz; Dexiang Gao; Michael Martini; Lindsay A Marek; Kathryn E Ware; Michael G Edwards; Diana Böhm; Sven Perner; Barbara A Helfrich; Rafal Dziadziuszko; Jacek Jassem; Szymon Wojtylak; Aleksandra Sejda; Joseph M Gozgit; Paul A Bunn; D Ross Camidge; Aik-Choon Tan; Fred R Hirsch; Lynn E Heasley
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

8.  A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population.

Authors:  J Sun; M Zhu; W Shen; C Wang; J Dai; L Xu; G Jin; Z Hu; H Ma; H Shen
Journal:  Pharmacogenomics J       Date:  2016-03-08       Impact factor: 3.550

9.  Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.

Authors:  Dariush Etemadmoghadam; Joshy George; Prue A Cowin; Carleen Cullinane; Maya Kansara; Kylie L Gorringe; Gordon K Smyth; David D L Bowtell
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

10.  Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.

Authors:  Ellen M Beauchamp; Brittany A Woods; Austin M Dulak; Li Tan; Chunxiao Xu; Nathanael S Gray; Adam J Bass; Kwok-kin Wong; Matthew Meyerson; Peter S Hammerman
Journal:  Mol Cancer Ther       Date:  2013-12-02       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.